There are still some debates about the therapeutic efficacy of different IFN-α therapies [105], although a phase 2 open-label, randomized clinical trial with moderate COVID-19 patients was used to evaluate the efficiency of pegylated interferon-alpha-2b (IFN-α-2b) [106]. The gene discussed is IFNA1; the disease is COVID-19.